EUVIMEDEUVIMED entdecken
Crossref

Mitogen-activated protein kinase inhibitor PD0325901 enhances radiosensitivity by modulating PD-1/PD-L1 through MEK/ERK pathway in cervical cancer cells

Q. Qin, C. Liu, J. Lu, J. Wang, Z. Li

International Journal of Radiation Research · 01.04.2026 · 24 (2) · 365-371

DOI: 10.66224/ijrr.24.2.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Research, online erschienen am 01.04.2026. Verfasst von Q. Qin und 4 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate the mechanism of mitogen-activated protein kinase (MEK) inhibitor PD0325901-mediated MEK/extracellular signal-regulated kinase (ERK1)/2 pathway on programmed death-1(PD-1) and ligand programmed death ligand-1(PD-L1) in cervical cancer (CC) cells.Materials and Methods: CC HeLa cells were divided into three groups: control (Group A), PD0325901 (100 nmol/L) (Group B), and Phorbol 12-myristate 13-acetate (PMA) (100 nmol/L PD0325901 + 10 μmol/L PMA) (Group C).The methodology used for simulation radiotherapy includes assessing cell viability at 12h and 24h using3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, apoptosis by Annexin V-FITC/PI method, invasion through Transwell assay, and gene expression by reverse transcription polymerase chain reaction (RT-PCR) and Western blot.PD0325901 was tested as a potential radiosensitizer by modulating PD-1/PD-L1 immune checkpoint expression and affecting the MEK/ERK pathway in simulated post-radiotherapy conditions.

Results

At 12h and 24h, cell viability in Group B was significantly lower than Group A, with increased apoptosis rates in Group B compared to Group A. Group C showed partial reversal of these effects.MEK/ERK1/2, PD-1, and PD-L1 expression were reduced in Group B, but upregulated in Group C, confirming the impact of PD0325901 on immune checkpoint modulation.

Conclusion

PD0325901 inhibits the MEK/ERK1/2 pathway, leading to suppression of PD-1/PD-L1 expression and enhanced apoptosis in cervical cancer cells, suggesting a potential role for PD0325901 in enhancing radiosensitivity by modulating immune checkpoint signaling.

Zitieren

APA

Qin, Q., Liu, C., Lu, J., Wang, J., & Li, Z. (2026). Mitogen-activated protein kinase inhibitor PD0325901 enhances radiosensitivity by modulating PD-1/PD-L1 through MEK/ERK pathway in cervical cancer cells. International Journal of Radiation Research, 24(2), 365-371. https://doi.org/10.66224/ijrr.24.2.10

Vancouver

Qin Q, Liu C, Lu J, Wang J, Li Z. Mitogen-activated protein kinase inhibitor PD0325901 enhances radiosensitivity by modulating PD-1/PD-L1 through MEK/ERK pathway in cervical cancer cells. International Journal of Radiation Research. 2026;24(2):365-371. doi:10.66224/ijrr.24.2.10

BibTeX
@article{Qin2026,
  author = {Qin, Q. and Liu, C. and Lu, J. and Wang, J. and Li, Z.},
  title = {Mitogen-activated protein kinase inhibitor PD0325901 enhances radiosensitivity by modulating PD-1/PD-L1 through MEK/ERK pathway in cervical cancer cells},
  journal = {International Journal of Radiation Research},
  year = {2026},
  volume = {24},
  number = {2},
  pages = {365--371},
  doi = {10.66224/ijrr.24.2.10}
}
Kostenlos starten →